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Abstract
Background:  The renin-angiotensin aldosterone system (RAAS) plays an important role in
regulating the blood pressure and the genetic polymorphisms of RAAS genes has been extensively
studied in relation to the cardiovascular diseases in various populations with conflicting results. The
aim of this study was to determine the association of five genetic polymorphisms (A6G and A20C
of angiotensinogen (AGT), MboI of renin, Gly460Trp of aldosterone synthase and Lys173Arg of
adducin) of RAAS genes in Malaysian essential hypertensive and type 2 diabetic subjects.
Methods: RAAS gene polymorphisms were determined using mutagenically separated PCR and
PCR-RFLP method in a total of 270 subjects consisting of 70 hypertensive subjects without type 2
diabetes mellitus (T2DM), 60 T2DM, 65 hypertensive subjects with T2DM and 75 control subjects.
Results: There was significant difference found in age, body mass index, systolic/diastolic blood
pressure, fasting plasma glucose and high density lipoprotein cholesterol levels between the
hypertensive subjects with or without T2DM and control subjects. No statistically significant
differences between groups were found in the allele frequency and genotype distribution for A20C
variant of AGT gene, MboI of renin, Gly460Trp of aldosterone and Lys173Arg of adducin (p > 0.05).
However, the results for A6G of AGT gene revealed significant differences in allele and genotype
frequencies in essential hypertension with or without T2DM (p < 0.001).
Conclusion: Among the five polymorphisms of RAAS genes only A6G variant of AGT gene was
significantly associated in Malaysian essential hypertensive and type 2 diabetic subjects. Therefore,
A6G polymorphism of the AGT gene could be a potential genetic marker for increased
susceptibility to essential hypertension with or without T2DMin Malaysian subjects.
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Background
It is well known that the renin angiotensin-aldosterone
system (RAAS) as a circulating or hormonal system that
regulates blood pressure, electrolyte and fluid homeosta-
sis [1]. The development of hypertension in diabetes is
also due to the effects of RAAS activation [2]. On the basis
of biochemical or physiological functions, genetic vari-
ants of angiotensin converting enzyme, angiotensinogen
(AGT), angiotensin type 1 receptor, aldosterone synthase
(CYP11B2), adducin, renin of RAAS have been intensively
studied in various populations with conflicting results in
relation to hypertension [3], diabetic complications [4],
coronary heart disease [5] and renal disease [6].
After an initial report [7], several studies analyzed the
association of AGT variants in relation to hypertension [8]
and diabetes [9] with conflicting results. Among the vari-
ants of AGT gene, A-20C variant (adenine-to-cytosine
transition at nucleotide -20) of the 5' upstream core pro-
moter region affects the transcription activity of AGT
mRNA and thereby alters the plasma AGT level and possi-
bly involved in the development of EHT [10]. Another
variant A for G substitution at position -6 in the core pro-
moter of the gene has been significantly associated with
elevated plasma AGT levels, AGT gene transcription and
EHT [11].
Renin plays a crucial role in the regulation of blood pres-
sure, and the renin gene (REN) is considered as a good
candidate quantitative trait locus involved in the etiology
of essential hypertension. The variations in the amount of
linkage disequilibrium have been observed at the human
REN gene locus indicating the importance of investigating
several REN gene polymorphisms. REN MboI two-allele
polymorphism of REN gene shows a positive association
with susceptibility to EHT [12,13] and also negative asso-
ciations [14].
Aldosterone plays an important role in controlling the
sodium balance, intravascular volume and in regulating
the blood pressure [15]. Aldosterone is synthesized from
deoxycorticosterone in the zona golmerulosa of adrenal
cortex by a mitochondrial cytochrome P450 enzyme,
CYP11B2 [16]. Mutations in CYP11B2 can lead to impor-
tant changes to arterial pressure and could be responsible
for hypertension. The haplotypes in CYP11B2 is strongly
associated with hypertension or plasma aldosterone con-
centrations [17]. An amino acid polymorphism showing
Lys173 rather than Arg173 in CYP11B2 gene has been
associated with low-renin hypertension in Japanese pop-
ulations [18].
Adducin is a heteromeric cytoskeleton protein composed
of α and β-subunits was the rate-limiting factor in RAAS,.
Variation in the α-adducin (ADD1) protein may affect ion
transport through modification of actin cytoskeleton
assembly and modulation of sodium pump activity [19]
and it has been suggested that defects in transport mecha-
nisms may be the cause of hypertension. Several studies
have suggested that the association or linkage of G- to-T
substitution polymorphism of amino acid residue 460 at
nucleotide position 614 of exon 10 of the α-Adducin gene
in EHT with controversial results in different populations
[20].
Hypertension is an extremely common co-morbidity of
diabetes and affects 70% of patients with diabetes and is
approximately twice as common in persons with diabetes
as in those without diabetes [21]. Several epidemiologic
studies show that the evidence for co-existence of hyper-
tension and diabetes is due to common genetic and envi-
ronmental factors such as diet, physical activity and age
interact with the genetic predisposition, leading to the
development of cardiovascular disease [22]. The patho-
genesis of hypertension in diabetes is complex and
involves several unified factors that collectively increase
the susceptibility to develop hypertension. There is a
strong association between up-regulation of RAAS, hyper-
tension and diabetes [2]. A short-term moderate hypergly-
cemia has been linked to an increase in plasma renin
activity, mean arterial pressure and renal vascular resist-
ance with activation of circulating and the local RAAS
[23]. RAAS genes are responsible for excess Angioyensin II
production or availability are possible candidates for
development of diabetic complications and the RAAS
gene polymorphisms has been extensively studied in var-
ious populations in relation to diabetic complications
[24].
The screening of candidate genes for nucleotide variants
that are associated with EHT and T2DM is a core compo-
nent of much diabetes and hypertension genetics
research. Several studies of the genetics of EHT and T2DM
have been analysed to select the candidate genes because
of known or presumed biological or physiological func-
tions. The choice of candidates is inevitably limited by our
incomplete understanding of the regulation of the proc-
esses and the pathophysiology of EHT and T2DM. More-
over there was no gene consistently associated with or
linked to EHT and T2DM [25,4].
The present study was undertaken to determine the possi-
ble association of two genetic variants of AGT gene and
one polymorphism from each of these candidate genes;
REN, CYP11B2 and ADD1 in Malaysian EHT with or with-
out T2DM and T2DM subjects.
Methods
Study subjects
A total of 195 patients were recruited from Universiti
Putra Malaysia (UPM) Physician Clinic, Hospital Kuala
Lumpur. Unrelated healthy individuals were collectedCardiovascular Diabetology 2009, 8:11 http://www.cardiab.com/content/8/1/11
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randomly (no age-sex matched controls) from UPM staff
members and volunteers. The subjects were divided into
four main groups: EHT without T2DM (group 1, No-70),
T2DM (group 2, No-60) EHT with T2DM (group 3, No-
65) and control subjects as group 4 (No-75). A question-
naire in both Malay and English languages were obtained
to asses the socio-demographic factors. Informed consent
was obtained from all the subjects who have participated
in this study. The protocol of this study was approved by
the Ethical Committee of the Faculty of Medical and
Health Sciences, Universiti Putra Malaysia (UPM/FPSK/
PADS/T-TAD/T7-MJKEtikaPPer/F01).
Physical measurements
Individual weight and heights were obtained to calculate
body mass index (BMI) using the formula, weight (kg)/
[height (m2)]. Hypertension was defined as ≥ 140 mmHg
of systolic blood pressure (SBP) and ≥ 90 mmHg of
diastolic blood pressure (DBP) or who were receiving
anti-hypertensive therapy. The blood pressure was meas-
ured on the right arm of the subjects using an automated
blood pressure monitor (Omron, Japan) by seated and
rested for 5 minutes. The fasting blood glucose levels were
obtained from the medical records of all the known dia-
betic subjects. For control subjects, fasting blood glucose
level was measured using MediSense Precision-G blood
glucose monitor.
DNA preparation
Four-five milliliters of blood samples were collected from
the peripheral venous blood into an EDTA tube (Becton
Dickinson, NJ) by a qualified phlebotomist. Genomic
DNA extraction was carried out using the DNA isolation
kit (BioBasic.Inc, Canada). The purity of extracted DNA
was quantified using Eppendorf UVette® in Biophotome-
ter (Eppendorf, Hamburg, Germany).
Biochemical analysis
Before the DNA extraction, serum was separated from the
blood by centrifuge at 4000 rpm and stored at -20°C until
further analysis. Serum levels of high-density lipoprotein-
cholesterol (HDL-C), total cholesterol (TC) and triglycer-
ides (TG) were measured enzymatically on a Hitachi-912
Autoanalyser (Mannheim, Germany) with kits supplied
by Roche Diagnostics (Mannheim, Germany). Low den-
sity lipoprotein cholesterol (LDL-C) was calculated using
Friedewald formula [26].
Determination of RAAS gene polymorphisms
Detection of A6G polymorphism of AGT gene and
Gly460Trp polymorphism of ADD1 was performed by
mutagenically separated PCR (MS-PCR) technique [27]
with both normal and mutant alleles were added together
in one reaction tube. The other polymorphisms (A20C,
MboI and Lys173Arg) were assayed by restriction analysis
of the PCR product with the respective restriction
enzymes.
The A6G polymorphism of AGT gene was amplified in a
25-μL reaction mixture contains the template DNA, 10
pmol/L of each three primers, 0.4 mmol/L each dNTP, 2
mmol/L MgCl2, 1× Taq buffer and 1 unit of NEB Taq DNA
polymerase (New England Biolabs, Beverly, MA, USA).
The temperature for initial denaturation step was 94°C
for 5 min, followed by 35 number of cycles, each of 94°C
for 45 seconds (s), 62°C for 45 s, and 72°C for 45 s, and
by a final extension at 72°C for 7 min. The amplification
reaction yields a 187-bp and a 207-bp product for the A-6
and G-6 alleles respectively [28].
PCR amplification was performed for Gly460Trp poly-
morphism of ADD1 gene in a 25-μL reaction mixture con-
tained 2.4 pmol/L of forward primer (FP)-1, 4.8 pmol/L
of FP-2 and 6 pmol/L of reverse primer (RP), 0.4 mmol/L
each dNTP, 2 mmol/L MgCl2, 1× Taq buffer and 1 unit of
NEB Taq DNA polymerase (New England Biolabs, Bev-
erly, MA, USA) and the template DNA. The initial dena-
turation was set up for 3 minutes at 95°C followed by 35
cycles of denaturation for 20 s at 94°C, annealing for 30 s
at 60°C, and extension for 30 s at 72°C [29-31]. The size
of the PCR products was 220 bp and 234 bp for the
460Gly and 460Trp alleles, respectively.
To determine the genotypes of MboI of REN, Gly460Trp of
CYP11B2 and Lys173Arg of ADD1 genes, genomic DNA
was amplified first by the respective primers (Table 1)
using polymerase chain reaction (PCR) technnique. The
PCR amplification for all the respective polymorphisms
was performed in total volume of 25-μL reaction mixture
consisting of 10 pmol of each primer, 0.3–0.4 mmol/L
each dNTP, 1.5–3.0 mmol/L MgCl2, 1× Taq buffer and 1
unit of NEB Taq DNA polymerase. The PCR products of
the respective primers was digested with 2–4 units of the
respective restriction enzymes (New England Biolabs,
Beverly, MA, USA) and incubated at 37°C for 3–5 hours
with the respective NEB buffers in a final volume of 20 μL
reaction mixture. The heat inactivation was done on the
basis of manufacture's protocol for the respective restric-
tion enzymes. A negative control containing no genomic
DNA and a positive control of known genotype were
always included in the set of reactions. All the PCR cycling
conditions were carried out on iCycler machine (BioRad
Laboratories, Hercules, California, USA). The amplified
PCR products for A6G and Gly460Trp polymorphisms
were separated on a 3% Metaphor agarose gel (Cambrex,
East Rutherford, NJ, USA), while other polymorphisms
were separated at 2–4% of agarose gel (Bioline, London,
UK) and performed in Origins electrophoresis tank
(Elchrom Scientific AG, Switzerland). The agarose gel was
stained in ethidium bromide and visualized using AlphaCardiovascular Diabetology 2009, 8:11 http://www.cardiab.com/content/8/1/11
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Imager (Alpha Innotech, San Leandro, CA). Table 1 shows
the primers used for RFLP method, PCR cycling condi-
tions, restriction endonucleases and the digested
restricted fragment size products. Identical results were
obtained when genotyping was performed for 10% of the
samples on two separate occasions.
Statistical analysis
All the statistical analysis was carried out by using SPSS
(Chicago, IL) software version 14.0 for Microsoft Win-
dows. Continuous variables were compared between the
groups by using two-tailed student's t test. Allelic frequen-
cies were calculated by gene-counting method and the
genotype distribution with Hardy-Weinberg expectations
by a chi-squared test. Odds ratios (OR) with 95% confi-
dence intervals (CI) were estimated for the effects of high
risk alleles. A level of P < 0.05 was considered statistically
significant.
Results and discussion
In detecting the association between the genetic polymor-
phisms and trait using association studies remains contro-
versial. However, it is an efficient method to evaluate the
associations of allele frequency or genotype frequencies of
candidate genes with diseases to understand the genetic
etiology of complex human traits [32]. Taking this into an
account, in this present study we determined the possible
association of genetic polymorphisms of RAAS genes with
EHT and T2DM in Malaysian subjects. To our knowledge,
few papers have been published in relation to RAAS gene
polymorphisms in Malaysian subjects. Probably this is the
first comprehensive reports on RAAS pathway gene poly-
morphisms in relation to EHT and T2DM in Malaysian
subjects.
Baseline characteristics
A total of 270 subjects were recruited in this study. Among
the subjects, 70 (25.93%) were hypertensive, 60 (22.22%)
Table 1: Oligonucleotides for amplification and screening for three polymorphisms using PCR-RFLP method
Gene polymorphism Forward primer (FP)
Reverse primer (RP)
PCR cycling conditions Restriction 
endonuclease
PCR product (bp) Restriction fragment 
size (bp)
A20C FP-5'-AGA GGT CCC 
AGC GTG AGT GTC-3'
RP-5'-AGC CCA CAG 
CTC AGT TAC ATC-3'
95°C- 3 m EcoO109I [10] 265 A-265 C-205,137
94°C- 1 m
64°C -1 m
72°C -1 m
72°C-5 m
X 30
MboI FP-5'-GAG GTT CGA 
GTC GGC CCC CT-3'
RP-5'-TGC CCA AAC 
ATG GCC ACA CAT-3'
94°C- 5 m MboI [30] 250 MboI (-) -250
94°C- 30 s MboI (+) -171, 79
68°C- 30 s
72°C- 30 s
72°C-5 m
X 30
Lys173Arg FP- 5'-AGG CAG CTT 
CTA CCA GGG CCC 
CAG TCA CT-3'
RP- 5'-CCC CTC CCC 
TGC AAA TCT CAT 
CCC TTA-3'
94°C- 3 m Bsu36I [31] 1286 L-1286, A- 1037, 249
94°C -45 s
61°C -45 s
72°C -1 m
72°C-10 m
X 35
PCR cycling conditions are represented as temperature and time [minute (m), seconds (s] of initial denaturation, denaturation, annealing, extension 
and final extension X number of cycles.Cardiovascular Diabetology 2009, 8:11 http://www.cardiab.com/content/8/1/11
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T2DM, 65 (24.07%) were hypertensive with T2DM and
75 (27.78%) unrelated healthy individuals. The majority
of the subjects in this study were males [163 (60.37%)]
compared to female subjects [107 (39.63%)]. Table 2
summarizes the clinical parameters of all the subjects.
According to American Diabetes Association, age plays a
significant role in the risk of developing T2DM and it is
most often seen in older adults. In this study, the median
age in the patient group was 57.21 years and the range was
31–84 years as compared to control group (median 45.37
years, range 30–74). Since the control group is younger
than the patient group, there was significant differences
found in age in all the three groups as compared with con-
trol group (p < 0.05). This is similar to a study done in
Malaysian hypertensive subjects [33] which shows that,
the hypertensive subjects ranged from 30 to 78 years old,
with a mean age of 54.7 years, while the normotensives
ranged from 25 to 78 years old, with a mean 49.3 years,
but, in contrast to the findings in Malays [34].
The subjects were stratified according to gender in hyper-
tensive subjects [51 (72.86%) males and 19 (27.14%)
females], T2DM [33 (55%) males and 27 (45%) females],
T2DM with EHT [40 (61.54%) males and 25 (38.46%)
females] and unrelated healthy individuals as controls [39
(52.00%) males and 36 (48.00%) females]. There was a
significant difference found in hypertensive subjects as
compared to normotensive subjects for gender which was
not similar to the prevalence of hypertension found in
Malaysian population [35]. The study shows [35] that the
prevalence of hypertension in males and females was not
significantly different above the age of 40 years, however,
aged 15–39 years, hypertension was significantly more
prevalent in males than females (P < 0.05) in Malaysian
population. Significant differences (p < 0.05) was
observed in age, BMI, DBP, FPG, HDL-C and Na in the
patient groups as compared to the control subjects. In
hypertensive subjects with or without T2DM, SBP, DBP,
BMI, FPG and Na was in higher levels while HDL-C was
lower in levels as compared to control subjects and signif-
icantly differed than those in controls. The variables of
SBP and DBP at the time of participation were signifi-
cantly higher in hypertensive groups than control group
(p < 0.001). The results, support the previous hypothesis
that the higher the blood pressure, the greater the risk of
heart attack, heart failure, stroke and kidney disease [36].
The presence of additional risk factors such as BMI and
high cholesterol levels increases the CVD risk from hyper-
tension [36]. However, other risk factors such as TC, high
LDL-C and low potassium were not significantly different
with control subjects. Among the patient groups, obesity
was clearly observed in T2DM (27.89 ± 3.93) as compared
to other subjects. However, in hypertensive subjects with
or without T2DM were under pre-obesity category 25.63 ±
4.15 and 26.71 ± 3.59 respectively as compared to over-
weight control subjects (23.91 ± 4.01). The BMI for the
Table 2: Baseline characteristics of the subjects
Parameters Group 1
(n-70)
Group 2
(n-60)
Group 3
(n-65)
Group 4
(n-75)
Gender
(male/female)
51/19* 33/27 40/25 39/36
Age
(Years)
57.70 ± 11.02* 57.70 ± 10.24* 57.61 ± 9.76* 45.37 ± 10.69
BMI
(kg/m2)
25.63 ± 4.15* 27.89 ± 3.93* 26.71 ± 3.59* 23.91 ± 4.01
SBP
(mm Hg)
159.44 ± 17.10* 125.93 ± 9.05 160.26 ± 19.01* 125.98 ± 8.81
DBP
(mm Hg)
96.40 ± 6.52* 74.97 ± 7.34 93.60 ± 3.77* 77.83 ± 7.09
FPG
(mmol/L)
5.24 ± 0.54* 11.85 ± 4.81* 11.68 ± 4.71* 4.60 ± 0.91
HDL-C
(mmol/L)
0.86 ± 0.31* 0.73 ± 0.22* 0.78 ± 0.29* 1.11 ± 0.40
LDL-C
(mmol/L)
3.42 ± 1.09 4.04 ± 1.47* 3.76 ± 1.19 3.36 ± 1.16
TG
(mmol/L))
1.97 ± 0.99 2.09 ± 1.01* 1.95 ± 0.87 1.64 ± 0.98
TC
(mmol/L
4.80 ± 1.10 5.14 ± 1.31 5.05 ± 1.26 5.12 ± 1.38
Na
(mEq/L)
144.17 ± 12.78* 133.01 ± 9.60* 137.12 ± 10.11* 114.73 ± 18.38
K
(mEq/L)
4.94 ± 1.15 4.90 ± 0.82 5.24 ± 0.92 5.13 ± 0.89
Data presented as mean ± SD, Group 1- EHT, Group 2 -T2DM, Group 3-EHT+T2DM and Group 4-Control subjects,* P value < 0.05 vs. Group 4Cardiovascular Diabetology 2009, 8:11 http://www.cardiab.com/content/8/1/11
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subjects in the patient groups were significantly different
from control subjects (p < 0.05) for BMI. Elevated serum
triglycerides strongly indicate the presence of metabolic
syndrome in patients with T2DM [37]. Only in type 2 dia-
betic patients, the concentration of LDL-C was signifi-
cantly different from control subjects and the type 2
diabetic subjects are at borderline high category (>3.36
mmol/l) according to NCEP ATPIII [38]. There was no sig-
nificant difference found in LDL in hypertensive subjects
with or without diabetes as compared to control group (p
> 0.05). Triglycerides was significantly differed only in
diabetic subjects (p < 0.05) but not in other groups. Total
cholesterol was not significantly differed between the
patient groups and the control subjects as they found
under desirable category according to NCEP ATPIII. The
aggregation of risk factors found in our study was another
determinant of the early occurrence of the disease. An ele-
vation in TG, and a reduction in HDL-C favored the
hypothesis that metabolic syndrome participates in the
development of early CAD [39].
Genotyping results
Genetic polymorphisms involved in RAAS genes suscepti-
bility to EHT and T2DM have been intensively scrutinized
by linkage and association studies in various populations.
The genes coding for each protein involved in the RAAS
have been identified and studied for any relation with
hypertension and other cardiovascular disorders [3,5].
Among the candidate genes of RAAS, AGT gene was con-
sidered as an important in the pathogenesis of EHT, since
angiotensin II, a potent vasoconstrictor and a stimulator
for aldosterone release which is obtained from the precur-
sor molecule angiotensinogen by the proteolysis activity
of renin and angiotensin converting enzyme [40]. Table 3
shows the genotypic and allelic frequency of RAAS gene
polymorphisms in the subjects along with odds ratio and
95% confidence interval. There was significant association
found only in A6G variant of AGT gene in Malaysian EHT
with or without T2DM subjects. Figures 1, 2, 3, 4, 5 shows
the genotypes of RAAS gene polymorphisms separated in
gel electrophoresis.
G allele of A6G variant shows nearly 90.91% among the
case subjects as compared to 9.09% of control subjects.
The frequency was higher than those reported in whites
but similar to that found in Japanese populations, sug-
gesting that the A26G variant shows a significant ethnic
difference [41,28]. Moreover, A6G variant found signifi-
cantly associated with group 3 subjects when compared
with control subjects (P-0.003) and was well accordance
with Chilean Hispanic hypertensive subjects [42]. How-
ever, the results were also in contrast to few studies done
in BMI subjects in Spanish population [43] and essential
hypertensive subjects in Han, Tibetan and Yi populations
[44] (p > 0.05). A previous report [33] suggested that
M235T variant of AGT gene was well associated with
Malaysian essential hypertensive patients. It has been well
supported with the results of this study which shows that,
AGT gene variants plays an important role in the patho-
genesis of EHT. Tests of promoter activity and DNA inter-
actions with factors involved in transcription initiation
influence the basal rate of transcription of the gene [41].
These observations provide some biological insight about
the possible mechanism by which individual differences
in the AGT gene may predispose to EHT.
There was no significant association in relation to geno-
type or allele distributions of A20C variant of AGT gene
found between the patients and the control subjects. CC
genotype of A20C variant shows very less percentage
(2.05%) among the case subjects as compared to 1.33% of
control subjects. The results of this study were well in
accordance with the previous studies done in EHT
patients from a Tibetan population [8] Japanese popula-
tion [10].
Based on linkage and sib-pair linkage analysis and associ-
ation studies, the effects of genetic variations in the REN
gene have been studied extensively in human population.
The results of various sib-pair analyses have been unsuc-
cessful in clearly implicating REN gene variations as the
etiological basis of hypertension [45]. MboI RFLP [30] is
located in intron 9 and is probably not a functional
genetic variation but shown strongly positive association
with hypertension in different population groups. How-
ever, a study [46] shows that genetic variations in linkage
disequilibrium with this site or in a nearby gene in linkage
disequilibrium may be directly implicated in an individ-
ual's genetic susceptibility to blood pressure dysregula-
tion. In support to that, another study shows that MboI
polymorphism was susceptibility to EHT in UAE popula-
tion [30]. In contrast to those studies, our study shows
that the genotypes and alleles of MboI polymorphism of
REN gene was not statistically significant difference
between the cases and control subjects (p > 0.05). The
MboI  (+) allele frequency in Malaysian hypertensive
(18.57%) and normotensive (13.33%) subjects was lower
than that in UAE population 51% and 36%, respectively,
20% and 24% observed in normotensive subjects in
North American and Japanese population respectively.
The findings of MboI polymorphism of REN gene of this
study was similar to the few studies which failed to show
an association between hypertensive and normotensive
subjects [47].
Several studies supported that, the variant in adducin gene
in rats affects renal function by modulating the overall
capacity of tubular epithelial cells to transport ions modi-
fying the assembly of the actin cytoskeleton [48]. Few
studies revealed that, the possible association of Trp alleleCardiovascular Diabetology 2009, 8:11 http://www.cardiab.com/content/8/1/11
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Table 3: Genotypic and allelic distributions of RAAS gene polymorphisms
Genotypes and Alleles Group 1
n (%)
Group 2
n (%)
Group 3
n (%)
Group 4
n (%)
A6G Genotypes
AA
43 (61.43) 50 (83.30) 40 (61.54) 68 (90.67)
AG 20 (28.57) 7 (11.70) 17 (26.15) 6 (8.00)
GG 7 (10.00) 3 (5.00) 8 (12.31) 1 (1.33)
A6G Alleles
C
106 (75.71) 107 (89.17) 97 (74.62) 142 (94.67)
T 34 (24.29) 13 (10.83) 33 (25.38) 8 (5.33)
p value
Odds ratio (95% CI)
< 0.001*
1.76 (0.08–0.39)
0.112
0.46 (0.19–1.16)
< 0.001*
1.66 (0.07–0.37)
-
A20C Genotypes
AA
46 (65.70) 37 (61.7) 45 (69.23) 53 (70.67)
AC 21 (30.00) 22 (36.7) 19 (29.23) 21 (28.00)
CC 3 (4.30) 1 (1.6) 1 (1.54) 1 (1.33)
A20C Alleles
A
113 (80.70) 96 (80.00) 109 (83.80) 127 (84.67)
C 27 (19.30) 24 (20.00) 21 (16.20) 23 (15.33)
p value
Odds ratio (95% CI)
0.437
0.76 (0.41–1.40)
0.336
0.72 (0.39–1.36)
0.871
0.94 (0.49–1.71)
-
MboI Genotypes
(-/-)
46 (65.71) 43 (71.67) 47 (72.31) 56 (74.67)
(-/+) 22 (31.43) 16 (26.67) 15 (23.08) 18 (24.00)
(+/+) 2 (2.86) 1 (1.67) 3 (4.62) 1 (1.33)
MboI Alleles
(-)
114 (81.43) 102 (85.00) 109 (83.85) 130 (86.67)
(+) 26 (18.57) 18 (15.00) 21 (16.15) 20 (13.33)
p value
Odds ratio (95% CI)
0.261
0.67 (0.36–1.27)
0.727
0.87 (0.44–1.73)
0.612
0.80 (0.41–1.55)
Lys173Arg Genotypes
Lys173/Lys
37 (52.86) 22 (36.66) 34 (52.31) 37 (49.33)
Lys173/Arg 31 (44.28) 37 (61.67) 30 (46.15) 37 (49.33)
Arg173/Arg 2 (2.86) 1 (1.67) 1 (1.54) 1 (1.34)
Lys173Arg Alleles
Lys173
105 (75.00) 81 (67.50) 98 (75.38) 111 (74.00)
Arg173 35 (25.00) 39 (32.50) 32 (24.62) 39 (26.00)
p value
Odds ratio (95% CI)
0.893
1.05 (0.62–1.79)
0.280
0.73 (0.43–1.24)
0.891
1.08 (0.63–1.85)
-
Gly460Trp Genotypes
Gly460/Gly
36 (51.43) 28 (46.67) 26 (40.00) 40 (53.33)
Gly460/Trp 13 (18.57) 21 (35.00) 17 (26.15) 21 (28.00)
Trp460/Trp 21 (30.00) 11 (18.33) 22 (33.85) 14 (18.67)
Gly460Trp Alleles
Gly460
85 (60.71) 77 (64.17) 69 (53.08) 96 (64.00)
Trp460 55 (39.29) 43 (35.83) 61 (46.92) 54 (36.00)
p value
Odds ratio (95% CI)
0.564
0.87 (0.54–1.40)
1.000
1.01 (0.61–1.66)
0.064
0.63 (0.39–1.03)
-
Data are reported as number of subjects with percent in parentheses, Group 1- EHT, Group 2 -T2DM, Group 3- EHT+T2DM and Group 4-
Control subjects,*P value < 0.001 vs. Group 4.Cardiovascular Diabetology 2009, 8:11 http://www.cardiab.com/content/8/1/11
Page 8 of 12
(page number not for citation purposes)
of Gly460Trp polymorphism of ADD1 was associated
with an increased risk of EHT and T2DM [20]. In the
present study, we could not detect any association of Trp
allele of Gly460Trp polymorphism of ADD1 in Malaysian
EHT with or without T2DM subjects. No association was
found between the Gly460Trp allele and hypertension in
Japanese population [29].
In relation with T2DM the genotypes and alleles of
Gly460Trp polymorphism shows no significant difference
with control subjects (P = 1.000) which is similar to study
done in Irish population [49] in relation with diabetic
nephropathy and Type 1 diabetes (P = 0.087). However,
there are still remains the possibility of ADD1 gene affects
membrane ion transport because we did not investigate
the effect on salt-sensitivity or response to diuretic treat-
ment. However, several studies suggest that a variant in
ADD1 gene on its own is insufficient to develop hyperten-
sion [19,20].
The three common polymorphic variants of CYP11B2; C-
344T at 5' distal promoter region of the gene, a mutation
in intron 2, and K173R (Lys173Arg) in exon 3 have been
extensively evaluated in relation to hypertension and car-
diovascular disease. Unpublished data shows that, C344T
variant of CYP11B2 is not associated with hypertension in
Malays; an ethnic population in Malaysia. Hence, this
study focus on the other variant Lys173Arg of CYP11B2
gene located at exon 3 which has been associated with low
renin hypertensive patients in Chilean populations [42].
In this study, the frequency of the variant A allele of
Lys173Arg polymorphism was seen very less in hyperten-
sive patients with T2DM (24.62%) as compared to control
subjects (26.00%). No difference in AA genotype fre-
quency was evident between hypertensive patients
(2.86%) and control subjects (1.34%). Our results were
totally diverged from the previous report [42] shows that
Arg 173 allele frequency (21%) in low renin hypertensive
Chilean subjects.
Table 4 shows the genotypic and allelic distributions of
RAAS gene polymorphisms between male and female sub-
Agarose gel electrophoresis showing the genotypes of RAAS  gene polymorphisms Figure 1
Agarose gel electrophoresis showing the genotypes 
of RAAS gene polymorphisms. Llane 1, 3 and 5 repre-
sents homozygous AA genotypes, lane 2, 4 and 6 represents 
homozygous GG genotypes and lane 7 shows the hetero-
zygous AG genotypes of A6G polymorphism of AGT gene.
lane 1 represents homozygous CC genotypes, lane 2 and 5  represents heterozygous AC genotypes and lane 3, 4, 6, and  7 represents homozygous AA genotypes of A20C polymor- phism of AGT gene Figure 2
lane 1 represents homozygous CC genotypes, lane 2 
and 5 represents heterozygous AC genotypes and 
lane 3, 4, 6, and 7 represents homozygous AA geno-
types of A20C polymorphism of AGT gene.
Lane 1 and 5 represents heterozygous Gly/Trp genotypes,  lane 2 represents homozygous Gly/Gly genotypes, lane 3, 4,  6 and 7 represents homozygous Trp/Trp genotypes of  Gly460Trp polymorphism of alpha-adducin gene Figure 3
Lane 1 and 5 represents heterozygous Gly/Trp geno-
types, lane 2 represents homozygous Gly/Gly geno-
types, lane 3, 4, 6 and 7 represents homozygous Trp/
Trp genotypes of Gly460Trp polymorphism of alpha-
adducin gene.
Lane 1, 2, 3 and 5 represents heterozygous Lys/Arg geno- types, lane 4 represents homozygous Lys/Lys genotypes and  lane 6 represents homozygous Arg/Arg genotypes of  Lys173Arg polymorphism of aldosterone synthase gene Figure 4
Lane 1, 2, 3 and 5 represents heterozygous Lys/Arg 
genotypes, lane 4 represents homozygous Lys/Lys 
genotypes and lane 6 represents homozygous Arg/
Arg genotypes of Lys173Arg polymorphism of aldos-
terone synthase gene.Cardiovascular Diabetology 2009, 8:11 http://www.cardiab.com/content/8/1/11
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jects. There was no significant difference was found in
either genotypic or allelic distribution in both male and
female subjects (p > 0.05).
Some evidence shows that modulation of the RAAS by use
of angiotensin-converting enzyme inhibitors or angi-
otensn II receptor blockers leads to improved insulin sen-
sitivity, glycemic control and possibly prevention of
T2DM [50]. This study failed to show significant associa-
tion between all the five genetic polymorphisms of RAAS
genes with T2DM. The reason might be the different
methods used or may occur due to racial differences or
heterogeneity of the population sampling bias or possibly
due to the environmental factors may contribute to the
negative associations [51]. Moreover, despite the consid-
erable controversy regarding the existence and importance
of ethnic differences in genetic effects for complex dis-
eases, it seems evident that genetic markers for proposed
gene-disease associations vary in frequency across popula-
tions. Association studies must be repeated in this popu-
lation to ensure that any association of candidate genes
with T2DM is pathogenetically significant.
Study limitations
The present study has to be interpreted within the context
of its limitations. The present study provided only the evi-
dences of the association between the genetic polymor-
phisms of RAAS genes with EHT and T2DM at the gene
level and we did not address the mechanism or the func-
tionality of the variants. The control subjects are not age,
sex matched and they are relatively young as compared to
case subjects. Further association/replication studies with
well-designed larger sample size subjects involving other
polymorphisms of RAAS genes in related to cardiovascu-
lar diseases is recommended.
Conclusion
Among the five polymorphisms of RAAS genes, only A6G
variant of AGT gene was significantly associated in EHT
with or without T2DM, other polymorphisms were failed
to show any significant association between the case and
control subjects. In conclusion, the present study implies
that genotyping for the A6G variant of AGT gene could in
the future become an important part of the clinical proc-
ess of risk identification for EHT and T2DM in Malaysian
population.
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